Alpharma, Inc.
U.S., global generics business sold to Actavis for $810M
Published in Pharma Investments, Ventures and Law Weekly, November 20th, 2005
The sale has been approved by the boards of directors of Alpharma and Actavis Group and is expected to close in the fourth quarter of 2005, pending regulatory and other customary approvals. Based upon preliminary estimates, Alpharma believes this transaction is accretive to the company's 2006 planned earnings assuming no transaction.
The company is retaining ownership of its Branded Pharmaceuticals, Active Pharmaceutical Ingredients, and Animal Health businesses, as well as ParMed Pharmaceuticals,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
More Articles from Pharma Investments, Ventures and Law Weekly
- Anika Therapeutics, Inc.
Hyaluronic acid-based therapy developer reports 57% increase in revenues - Arena Pharmaceuticals, Inc.
Obesity drug developer records loss of $0.46 per share - AtheroGenics, Inc.
Chronic inflammatory disease drug maker posts loss of $0.61 per share - Bio-Bridge Science
Vaccine maker listed on OTCBB - BioSyntech, Inc.
Agreement signed with Korean pharmaceutical company for purchase of 1.5M shares of stock - Bioniche Life Sciences, Inc.
Bladder cancer drug developer signs agreement for private financing - More from this issue of Pharma Investments, Ventures and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
